Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results
Celcuity’s stock price skyrocketed on October 20, 2025 after the Minneapolis-based biotech reported game-changing clinical trial results. Shares jumped from around $52 to as high as $78–$81 intradaymarketbeat.com, an approximately 40–50% single-day leap, before settling near a record high close. This surge marked a new 52-week high of $81.56marketbeat.com and lifted Celcuity’s market capitalization above $2.2 billioninvesting.com. The stunning rally came on unusually heavy trading volume as investors rushed to buy shares, propelled by news from a major cancer conference. The immediate catalyst was Celcuity’s Phase 3 VIKTORIA-1 trial data presented over the weekend at the European Society for Medical Oncology Congress. The company’s lead drug candidate, gedatolisib – a pan-PI3K/mTOR inhibitor licensed from Pfizer – is being tested in combination therapies for advanced hormone receptor-positive, HER2-negative breast cancer. Celcuity’s Monday morning press release and conference call highlighted remarkably strong efficacy results, which in turn ignited bullish sentiment around the stock.
